Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CRITICS-II
Multicentric Randomised Trial for Resectable Gastric Cancer
- NCT02931890 ↗
- Active, not recruiting
- The Netherlands Cancer Institute
- Standard
We haven't built an HCP commentary report on CRITICS-II (docetaxel plus oxaliplatin plus capecitabine; paclitaxel plus carboplatin in resectable gastric cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CRITICS-II so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Multicentre Randomised Phase II Trial of Neo-adjuvant Chemotherapy Followed by Surgery vs. Neo-adjuvant Chemotherapy and Subsequent Chemoradiotherapy Followed by Surgery vs. Neo-adjuvant Chemoradiotherapy Followed by Surgery in Resectable Gastric Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Gastric Cancer
- Interventions
- Docetaxel; Oxaliplatin; Capecitabine; gastrectomy; radiotherapy of gastric cancer; Paclitaxel; Carboplatin
- Arms
- neo-adjuvant chemotherapy followed by surgery · Active comparator
- neo-adjuvant chemo and subsequent CRT followed by surgery · Active comparator
- neo-adjuvant chemoradiotherapy followed by surgery · Active comparator
- Enrollment
- 207 (estimated)
- Primary outcomes
- Event-Free survival
- Sponsor
- The Netherlands Cancer Institute
- Start
- Dec 21, 2017
- Primary completion
- Apr 2025 (estimated)
- Results posted
- No
- Registry record
- NCT02931890 · updated May 2, 2024
Publications
linked from the registry- Klute KA, Shah MA. Evolving Therapeutics for Resectable Esophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257044. doi: 10.6004/jnccn.2025.7044. PubMed 40340830
- Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018 Sep 10;18(1):877. doi: 10.1186/s12885-018-4770-2. PubMed 30200910